Ocugen, Inc. targets next generation brain gene therapies with new delivery approaches

Ocugen, Inc. targets next generation brain gene therapies with new delivery approaches
Ocugen, Inc. explores CNS gene delivery

Ocugen, Inc. is shedding light on emerging barriers and solutions in the field of brain-targeted gene therapies. In a recent publication in Molecular Therapy, Chief Scientific Officer Dr. Upadhyay and Scientific Writer Dr. Kunal Dayma examine the complexities of central nervous system gene delivery and highlight innovative strategies poised to advance research in neurological disorders such as Parkinsons and Alzheimers.

The work, published in collaboration with Cell Press, reviews the current state of gene therapy delivery methods for the brain, while proposing future directions that could accelerate progress in patient treatment.

Ocugen has previously focused on gene therapies for rare genetic retinal diseases, aiming to preserve vision through modifier gene therapy approaches. The company is also advancing OCU410 to address geographic atrophy, a severe form of dry age-related macular degeneration impacting millions of patients, according to recent development updates. These initiatives reflect Ocugen's ongoing work in developing targeted genetic treatments for complex disorders.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.